Abbisko Cayman (FRA:8ZD) Accounts Payable: €0.00 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8ZD Abbisko Cayman Ltd FRA:8ZD
55 GF Score
Price €1.18
GF Value €1.38
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Abbisko Cayman Accounts Payable?

Abbisko Cayman FRA:8ZD -0.84% 55 Accounts Payable is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:8ZD with a GF Score™ of 55/100 and a GF Value™ of €1.38 (Fairly Valued). The stock has 6 warning signs investors should review.

Abbisko Cayman's Accounts Payable for the quarter that ended in Dec. 2025 was €0.00 Mil.

Abbisko Cayman Accounts Payable Related Terms

Abbisko Cayman Accounts Payable Historical Data

* Premium members only.

The historical data trend for Abbisko Cayman's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Abbisko Cayman Accounts Payable Chart

Abbisko Cayman Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Abbisko Cayman Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:8ZD
55GF Score
Abbisko Cayman Ltd FRA:8ZD
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Abbisko Cayman Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of €0.00 Mil mean?
Abbisko Cayman (FRA:8ZD) has a Accounts Payable of €0.00 Mil as of Dec. 2025. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Abbisko Cayman and its competitors.
Is Abbisko Cayman's Accounts Payable too high?
Abbisko Cayman's current Accounts Payable is €0.00 Mil. Overall, Abbisko Cayman has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Accounts Payable compare to VRTX and REGN?
Abbisko Cayman's Accounts Payable of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Abbisko Cayman and its competitors. Abbisko Cayman's current Accounts Payable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (FRA:8ZD) is currently considered Fairly Valued. The stock's GF Value™ is €1.38, compared to a current price of €1.18 — trading 14.5% below its estimated fair value. The current Accounts Payable is €0.00 Mil. Abbisko Cayman's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Abbisko Cayman (FRA:8ZD), the current Accounts Payable is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Abbisko Cayman (FRA:8ZD) Overvalued in 2026?

Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued. The current stock price of €1.18 is trading 14.5% below its estimated GF Value™ of €1.38. GuruFocus considers Abbisko Cayman to be Fairly Valued.

Key valuation signals for FRA:8ZD:

  • Accounts Payable: €0.00 Mil
  • GF Value™: €1.38 vs. price of €1.18 (14.5% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the FRA:8ZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Abbisko Cayman Business Description

Other Exchanges 02256:Hong Kong
Address Building 3, No. 898 Halei Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, CHN
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
55GF Score

Get the complete analysis for FRA:8ZD

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.18
Price
€1.38
GF Value